1st approved Symbicort generic, Breyna, now available in US
WEBAug 7, 2023 · The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available to eligible patients.. Like Symbicort, Breyna is approved as a maintenance therapy to lower airflow obstruction and prevent exacerbations in people with COPD, and for asthma patients, ages 6 …
Low-dose Morphine Improves Health in COPD Patients With …
WEBSep 3, 2020 · So, researchers based at the Maastricht University in the Netherlands designed the Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) Phase 4 study (NCT02429050).It investigated whether regular, low-dose, oral sustained-release morphine improved health in COPD patients with moderate-to …
COPD Trial Shows Breztri Aerosphere Significantly Reduces...
WEBJun 30, 2020 · The findings were presented by the company at the American Thoracic Society virtual Scientific Symposium and published in The New England Journal of Medicine, in an article titled “ Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.”. Breztri Aerosphere, known as PT010 outside of China, is a triple combination therapy made up of the inhalable corticosteroid ...
Zephyr Valve Boosts Lung Function, Life Quality for COPD Patients:...
WEBMay 27, 2021 · Previous data from the trial indicated that, six months after treatment, participants given BLVR had significantly better lung function and quality of life than those treated with best standard care alone.. Newly presented data came from participants for whom longer-term data was available, including 48 patients with complete data up to 12 months, 40 with data up to 18 months, and 39 with data ...
LupinHaler, generic version of Spiriva HandiHaler, available in US
WEBAug 28, 2023 · In Europe, generics of Boehringer Ingelheim’s Spiriva HandiHaler began launching in 2021, including ones from Glenmark Pharmaceuticals and Phargentis, but these medications haven’t become available in the U.S.. COPD is a chronic lung disease wherein the airways become blocked, leading to progressively worsening disease symptoms that include shortness of breath and wheezing.
Trelegy Ellipta Reduces COPD Exacerbations and Improves Lung …
WEBApr 24, 2018 · The Phase 3 IMPACT study compared Trelegy to other common COPD medications in 10,355 patients in 37 countries, according to GlaxoSmithKline (GSK) and Innoviva.. Findings from the study, titled “Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD,” were recently published in the New England Journal of Medicine. Trelegy Ellipta was approved as a maintenance treatment ...
Stem Cell Therapy Seen to Help COPD Patients with Severe …
WEBJun 4, 2020 · During ISCT, Mesoblast presented a post-hoc analysis of a Phase 2 trial (NCT00683722) that investigated the safety and efficacy of multiple doses of remestemcel-L in patients with moderate-to-severe COPD.The trial, which concluded in August 2010, enrolled 62 patients who were randomly assigned to either four monthly intravenous infusions of remestemcel-L, containing about 100 million MSCs or ...
Duaklir Now Available to COPD Patients in the U.S.
WEBOct 29, 2019 · Duaklir has been approved globally, including in the European Union, under different brand names. Its approval was based on findings from three Phase 3 clinical trials — ACLIFORM (NCT01462942), AUGMENT (NCT01437397), and AMPLIFY (NCT02796677) — and the Phase 4 ASCENT-COPD study (NCT01966107).These trials showed that Duaklir effectively reduced the number of COPD flare-ups, and improved ...
AstraZeneca COPD Data Shows Breztri Aerosphere Better for All …
WEBSep 8, 2020 · That data will be presented by AstraZeneca — the developer of both Breztri Aerosphere and Bevespi Aerosphere — at the European Respiratory Society (ERS) International Virtual Congress 2020, held online Sept. 7-9, according to a company press release.. A triple combination therapy, Breztri Aerosphere contains the corticosteroid budesonide, as well as two types of bronchodilators ...
Ensifentrine as COPD maintenance therapy up for FDA approval
WEBJul 3, 2023 · Better FEV1 seen with ensifentrine’s use in ENHANCE-1 and -2 studies “The ENHANCE trials demonstrate ensifentrine’s outstanding ability to reduce the rate and risk of COPD exacerbations and to provide meaningful improvements in lung function and symptoms in a broad COPD population,” Antonio Anzueto, MD, the study’s first author and a professor of medicine and pulmonary section chief ...